Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome.
BACKGROUND
Subjects with metabolic syndrome (MetS) exhibit impaired lipoprotein metabolism and have an increased risk of cardiovascular disease. Although the risk is attributed primarily to the risk associated with individual components, it is also likely affected by other associated metabolic defects. Remnants of postprandial lipoproteins show potent atherogenicity in cell and animal models of insulin resistance and in pre-diabetic subjects with postprandial dyslipidemia. However, few studies have considered regulation of chylomicron remnant homeostasis in MetS per se. This study measured the plasma concentration in Caucasian men and women of small dense chylomicrons following fasting and explored associations with metabolic and anthropometric measures.


METHODS
A total of 215 Australian Caucasian participants (median age 62 years) were investigated. Of them, 40 participants were classified as having MetS. Apolipoprotein (apo) B-48, an exclusive marker of chylomicrons, metabolic markers and anthropometric measures were determined following an overnight fast.


RESULTS
The fasting apo B-48 concentration was 40 % higher in subjects with MetS than those without MetS. In all subjects, triglyceride (r = 0.445, P < 0.0005), non-HDL cholesterol (r = 0.28, P < 0.0005) and HDL cholesterol concentration (r = -0.272, P < 0.0005) were weakly associated with apo B-48 concentration. In subjects with MetS, the association of apo B-48 with triglyceride and non-HDL cholesterol was enhanced, but neither were robust markers of elevated apo B-48 in MetS (r = 0.618 and r = 0.595 respectively). There was no association between apo B-48 and HDL cholesterol in subjects with MetS.


CONCLUSIONS
This study demonstrates a substantial accumulation of pro-atherogenic remnants in subjects with MetS. We have shown that in a Caucasian cohort, the fasting plasma concentration of triglyceride or HDL/non-HDL cholesterol serves as poor surrogate markers of atherogenic chylomicron remnants. These findings suggest that subjects with MetS exhibit a chronic defect in chylomicron metabolism that is likely to contribute to their increased CV risk.
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.|Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.|Faculty of Medicine, Mataram University, West Nusa Tenggara, Indonesia.
Deasy
D
Irawati
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.|Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
John C L
JC
Mamo
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.|Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
Satvinder S
SS
Dhaliwal
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.|Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
Mario J
MJ
Soares
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia.
Karin M
KM
Slivkoff-Clark
School of Public Health, Faculty of Health Sciences, Curtin University, Bentley, GPO Box U1987, Perth, WA, 6845, Australia. T.P.James@curtin.edu.au.|Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia. T.P.James@curtin.edu.au.
Anthony P
AP
James
Apolipoprotein B-48; Chylomicron; Metabolic syndrome
Endocrine. 2016 Dec;54(3):588-601
27038318
J Clin Lipidol. 2008 Aug;2(4):267-73
21291742
Clin Biochem. 2003 Sep;36(6):421-9
12951168
J Clin Invest. 1991 Dec;88(6):2059-66
1752964
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1595-600
12842838
Atherosclerosis. 1996 Aug 2;124(2):221-35
8830935
Eur J Clin Invest. 1998 May;28(5):379-84
9650011
Eur Heart J. 2007 Apr;28(7):857-64
17303589
Circulation. 2005 Aug 2;112(5):666-73
16061755
J Atheroscler Thromb. 2009 Mar;16(1):12-20
19262003
Int J Vasc Med. 2012;2012:784536
22007304
Diabetes. 2006 May;55(5):1316-26
16644688
J Biol Chem. 2002 Aug 30;277(35):31646-55
12070142
Clin Chem Lab Med. 2003 Jun;41(6):792-5
12880143
Exp Biol Med (Maywood). 2004 Jun;229(6):528-37
15169972
Biochim Biophys Acta. 1996 May 20;1300(3):151-70
8679680
J Clin Invest. 1993 Nov;92(5):2191-8
8227334
Eur J Clin Invest. 2012 Jul;42(7):702-8
22224712
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
17957034
Clin Chim Acta. 2012 Jan 18;413(1-2):160-5
21958700
Nutr Metab Cardiovasc Dis. 2008 Oct;18(8):531-8
18321693
Clin Biochem. 2000 Oct;33(7):549-55
11124340
Clin Sci (Lond). 2004 Sep;107(3):233-49
15225143
Clin Sci (Lond). 2000 Feb;98(2):183-92
10657274
Circulation. 2009 Oct 20;120(16):1640-5
19805654
Circulation. 1979 Sep;60(3):473-85
222498
Clin Chim Acta. 2008 Apr;390(1-2):38-43
18206113
Coron Artery Dis. 1994 Aug;5(8):695-705
8000623
Clin Chim Acta. 2005 Jan;351(1-2):115-20
15563879
Atherosclerosis. 2005 Aug;181(2):345-51
16039289
Atheroscler Suppl. 2015 Feb;17:12-6
25659871
Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1357-63
16614317
J Lipid Res. 2003 Jun;44(6):1256-62
12671037
Coron Artery Dis. 1996 Mar;7(3):239-45
8827411
J Atheroscler Thromb. 2009 Aug;16(4):517-22
19713673
Curr Opin Lipidol. 2012 Aug;23(4):398-9
22801390
J Lipid Res. 2012 Aug;53(8):1451-8
22679067
Atherosclerosis. 2015 Nov;243(1):236-41
26407667
Eur J Clin Invest. 2012 Sep;42(9):992-9
22587365
Clin Biochem. 2009 Sep;42(13-14):1331-46
19501581
Eur J Nutr. 2016 Jun;55(4):1503-13
26130325
Curr Opin Lipidol. 2010 Jun;21(3):218-28
20463470
Am J Med. 2006 Oct;119(10):812-9
17000207
J Atheroscler Thromb. 2014;21(6):618-27
24573016